Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.
Peters RPH, Klausner JD, Mazzola L, Mdingi MM, Jung H, Gigi RMS, Piton J, Daniels J, de Vos L, Adamson PC, Gleeson B, Ferreyra C. Peters RPH, et al. Among authors: mazzola l. Lancet. 2024 Feb 17;403(10427):657-664. doi: 10.1016/S0140-6736(23)02240-7. Epub 2024 Feb 6. Lancet. 2024. PMID: 38335982 Free PMC article.
Usability of a novel lateral flow assay for the point-of-care detection of Neisseria gonorrhoeae: A qualitative time-series assessment among healthcare workers in South Africa.
de Vos L, Daniels J, Gebengu A, Mazzola L, Gleeson B, Piton J, Mdingi M, Gigi R, Ferreyra C, Klausner JD, Peters RPH. de Vos L, et al. Among authors: mazzola l. PLoS One. 2023 Jun 2;18(6):e0286666. doi: 10.1371/journal.pone.0286666. eCollection 2023. PLoS One. 2023. PMID: 37267319 Free PMC article.
Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study.
de Vos L, Daniels J, Gebengu A, Mazzola L, Gleeson B, Blümel B, Piton J, Mdingi M, Gigi RMS, Ferreyra C, Klausner JD, Peters RPH. de Vos L, et al. Among authors: mazzola l. BMC Health Serv Res. 2024 Jan 9;24(1):43. doi: 10.1186/s12913-023-10478-8. BMC Health Serv Res. 2024. PMID: 38195446 Free PMC article.
Electro-Clinical Features and Functional Connectivity Analysis in SYN1-Related Epilepsy.
Moya Quiros V, Adham A, Convers P, Lesca G, Mauguiere F, Soulier H, Arzimanoglou A, Bayat A, Braakman H, Camdessanche JP, Casenave P, Chaton L, Chaix Y, Chochoi M, Depienne C, Desportes V, De Ridder J, Dinkelacker V, Gardella E, Kluger GJ, Jung J, Lemesle Martin M, Mancardi MM, Mueller M, Poulat AL, Platzer K, Roubertie A, Stokman MF, Vulto-van Silfhout AT, Wiegand G, Mazzola L. Moya Quiros V, et al. Among authors: mazzola l. Ann Neurol. 2024 Aug 23. doi: 10.1002/ana.27063. Online ahead of print. Ann Neurol. 2024. PMID: 39177219
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade.
Moore KA, Ostrowsky JT, Mehr AJ, Johnson RA, Ulrich AK, Moua NM, Fay PC, Hart PJ, Golding JP, Benassi V, Preziosi MP, Adetifa IM, Akpede GO, Ampofo WK, Asogun DA, Barrett ADT, Bausch DG, de Coster I, Emperador DM, Feldmann H, Fichet-Calvet E, Formenty PBH, Garry RF, Grant DS, Günther S, Gupta SB, Jaspard M, Mazzola LT, Okogbenin SA, Roth C, Schmaljohn CS, Osterholm MT. Moore KA, et al. Among authors: mazzola lt. Lancet Infect Dis. 2024 Nov;24(11):e696-e706. doi: 10.1016/S1473-3099(24)00229-9. Epub 2024 Jul 1. Lancet Infect Dis. 2024. PMID: 38964363 Review.
Measures to prevent and treat Nipah virus disease: research priorities for 2024-29.
Moore KA, Mehr AJ, Ostrowsky JT, Ulrich AK, Moua NM, Fay PC, Hart PJ, Golding JP, Benassi V, Preziosi MP, Broder CC, de Wit E, Formenty PBH, Freiberg AN, Gurley ES, Halpin K, Luby SP, Mazzola LT, Montgomery JM, Spiropoulou CF, Mourya DT, Parveen S, Rahman M, Roth C, Wang LF, Osterholm MT. Moore KA, et al. Among authors: mazzola lt. Lancet Infect Dis. 2024 Nov;24(11):e707-e717. doi: 10.1016/S1473-3099(24)00262-7. Epub 2024 Jul 1. Lancet Infect Dis. 2024. PMID: 38964362 Review.
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Venet M, Lepine A, Maarouf A, Biotti D, Boutiere C, Casez O, Cohen M, Durozard P, Demortière S, Giorgi L, Maillart E, Mathey G, Mazzola L, Rico A, Camdessanche JP, Deiva K, Pelletier J, Audoin B. Venet M, et al. Among authors: mazzola l. Mult Scler. 2024 Feb;30(2):261-265. doi: 10.1177/13524585231223069. Epub 2024 Jan 2. Mult Scler. 2024. PMID: 38166437
100 results